Puma Biotechnology, Inc. (PBYI) Stock Score, Valuation & Financial Research
Puma Biotechnology, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for PBYI
Puma Biotechnology, Inc. currently has a Wall Street Score of 35/100. The stored market price is $9.14. Its financial score is 40/100. Its valuation score is 22/100. These figures are a research snapshot, not a buy or sell recommendation.
What Puma Biotechnology, Inc. does
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology m
PBYI financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $9.14
- Market capitalization:
- $465.2M
- Revenue:
- $227.2M
- Net income:
- $24.4M
- Free cash flow:
- $41.7M
- Cash:
- $36.2M
- Total debt:
- $16.0M
- EPS:
- 0.62
- P/E ratio:
- 14.7x
- Financial score:
- 40/100
- Valuation score:
- 22/100
- Revenue score:
- 16/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $41.7M, showing positive cash generation.
- The balance sheet shows $36.2M of cash versus $16.0M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 22/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 40/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PBYI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.